Brazil: Selection Invention In The Pharmaceutical Area: An Overview Of The Legal Opinions PTO And ANVISA Have On The Issue

A selection invention is one in which a single element or small segment within a broad known group is selected and claimed in an independent way, based on a particular feature that is not mentioned in the broader group.

The patents that use a Markush-type formula to claim a compound are one of the most common examples to illustrate a selection invention in the chemical/pharmaceutical area. A Markush-type formula has various radicals with vast possibilities of possible substituents that can be chosen. The combinations of all the possibilities of the radicals may lead to a large number of compounds, some of which are neither studied nor described in the patent application. A selection invention consists of the selection of specific substituents that bring about a different compound with surprising properties in relation to the broader compound from which the selection was made.

A more practical example to illustrate the selection inventions is the selection of parameters in a process. For example, a process uses a temperature range between 50 and 200ºC and a pressure range between 40 and 90 Pa and the yield from it is X. It was verified that the yield of the process had tripled using a temperature of 58ºC with a pressure of 72 Pa but such conditions were not tested or described in the prior art. This process with the selection of specific conditions and the provision of a superior result may also be used as an example for selection inventions.

Brazilian law has no impediment to granting patents for selection inventions and such inventions should be analyzed using the same patentability criteria of the other inventions, i.e. innovation, inventive activity and industrial use.

Although there is no distinction in Brazilian law in relation to this kind of invention, the patentability of the selection inventions is being increasingly more discussed. This discussion mainly involves questions related to public health and the economy as a large part of the selection inventions are related to pharmaceutical patents.

In March 2015, the Brazilian Patent and Trademark Office (PTO) put forward a proposal for public consultation on the guidelines for patent application exams that discusses some conditions that should be considered in the exam of a selection invention and provides some guidance for the examiners to follow in examining an invention of this kind.

The highlights among the main guidelines presented were the presentation of concepts to characterize a selection and the provision of some situations exemplifying them to determine whether the selection could be regarded as obvious or not. The PTO´s opinion, reflected in these guidelines, is that the selection should represent an independent invention and/or a new breakthrough and should not be a mere arbitrary selection in relation to the prior art. Moreover, if a specific member of the broadest group from which the selection originated already showed this feature, the selection would not have an inventive activity.

This document reflects the concern and importance with which the PTO should deal with this subject as it also indicates that Brazil is moving towards an agreement with the opinion of a number of patent offices worldwide, such as the EPO, USPTO and JPO.

It is extremely difficult to create a new molecule at this time, even with the high investments in research, development and technology. As a result, many pharmaceutical companies are investing in incremental inventions in an attempt to develop innovation in the pharmaceutical sector. The selection inventions, which are incremental inventions, are a real alternative for the development of new drugs and these companies have paid great attention to these possibilities.

The patent system in the pharmaceutical area can be analyzed through two prisms, i.e. the first is that the innovation favors the creation of new drugs and the second is that the patent protection of drugs may make access to the medicament difficult. The selection inventions offer the possibility of a very large increase in the availability to society as a whole of new drugs but, on the other hand, it may be used as a strategy to extend the expiry of the patent. These are the cases known as evergreening.

Considering that the selection inventions protect new inventions and inventive activities that are different from the originating patent and meet all the requirements for the granting of a patent established by law, it does not make sense to interpret this kind of patent as an extension of the period of protection of the originating patent.

In Brazil, the patent exams in the pharmaceutical area are also carried out by ANVISA (National Health Surveillance Agency)[2]. The granting of a pharmaceutical patent requires the prior approval of ANVISA for it to be then examined by the PTO. ANVISA usually analyzes the applications that are regarded as being of interest to the drug and pharmaceutical care policies of the public health service, known as the SUS

The Federal Public Attorney (PGF) established, on October 16, 2009, that the institutional prerogatives of the PTO and ANVISA were specific and proprietary and should not be confused or even overlap. The PGF concluded that it was not ANVISA´s prerogative when carrying out a prior approval exam to undertake an analysis based on the patentability criteria as this would be the PTO´s own and unique prerogative. Furthermore, the PGF ruled that ANVISA should, in the prior approval analysis, act within the limits of its competence, i.e. to prevent the production and sale of products and services that were potentially harmful to human health. The PGF´s opinion was also adopted by a number of public bodies, such as the Federal Regional Courts of the 1st and 2nd regions, the Public Prosecutor´s Office and the Federal Courts of the Federal District.

Despite this ruling established by the PGF, ANVISA carries out a patentability criteria exam on examining a patent application when the patent in question is of interest to the SUS. Moreover, although the exam of the patent applications is conducted under the same legal provision, the ANVISA adopts a different position from that of the PTO. ANVISA´s present policy is against granting selection inventions and for a second medical use, for example.

As a result, a selection invention in the pharmaceutical area that was included within the SUS´s policies of interest would be highly unlikely to receive the prior approval from ANVISA.

This difference of opinion between the PTO and ANVISA creates legal uncertainty for investors in research, development and innovation in the pharmaceutical area. The holders of these patent applications are currently having to make legal appeals to have some idea of what will happen to their cases. To reduce this legal uncertainty, it is essential that ANVISA acts within the limits of its competence when examining a patent application and not carry out any patentability exam which is the prerogative of the PTO.

The PTO recently asked to intervene in a legal case involving the holder of a patent application and ANVISA to express its opinion on the matter. According to the PTO´s opinion, the ANVISA technical opinions that denied the prior approval of the patent application in question should have been challenged as ANVISA identified no dangers to public health in its opinions. The PTO concluded that there was no legal backing for ANVISA to reject the prior approval of the application as no such risks to health had been identified.

This active positioning by the PTO in this legal case strengthens the ruling established by the PGF and increases the prospects that the exam carried out by ANVISA will be limited purely to its field of activity, i.e. ANVISA will not evaluate the patentability requirements of a patent application.

Therefore, we can conclude that the practice of innovation and strategy of incremental innovation may have benefits in the pharmaceutical sector, as long as they are not used to extend the expiry of a patent but employed to develop new products in such a way as to bring greater popular access to the drugs.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions